<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32306421</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1768-322X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>112</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biology of the cell</Title>
          <ISOAbbreviation>Biol Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>REV-ERBα activates the mTOR signalling pathway and promotes myotubes differentiation.</ArticleTitle>
        <Pagination>
          <StartPage>213</StartPage>
          <EndPage>221</EndPage>
          <MedlinePgn>213-221</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/boc.201900091</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND INFORMATION" NlmCategory="BACKGROUND">Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) is a master regulator of cell and whole-body energy homoeostasis. REV-ERBα is a nuclear receptor that plays an important role in metabolism. While mTORC1 activation is necessary for muscle differentiation, the role of REV-ERBα is less clear.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We studied the effect of REV-ERBα overexpression and silencing as well as mTORC1 activation and inhibition on the differentiation of C2C12 myoblasts to myotubes. mTOR, myogenin and REV-ERBα were induced during differentiation of myoblasts into myotubes. REV-ERBα was found to activate mTORC1 during the differentiation process even in the absence of the differentiation medium. This activation was presumably through the downregulation of the expression of TSC1, an mTORC1 inhibitor.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Herein we show that REV-ERBα promotes myoblasts differentiation via the activation of the mTORC1 signalling pathway.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">REV-ERBα modulation can activate mTORC1 signalling and promote myoblasts differentiation.</AbstractText>
          <CopyrightInformation>© 2020 Société Française des Microscopies and Société de Biologie Cellulaire de France. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dadon-Freiberg</LastName>
            <ForeName>Maayan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, 76100, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chapnik</LastName>
            <ForeName>Nava</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, 76100, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Froy</LastName>
            <ForeName>Oren</ForeName>
            <Initials>O</Initials>
            <Identifier Source="ORCID">0000-0001-9061-3780</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, 76100, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biol Cell</MedlineTA>
        <NlmUniqueID>8108529</NlmUniqueID>
        <ISSNLinking>0248-4900</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498262">Nr1d1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056953">Nuclear Receptor Subfamily 1, Group D, Member 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018485" MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032446" MajorTopicYN="N">Myoblasts</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056953" MajorTopicYN="N">Nuclear Receptor Subfamily 1, Group D, Member 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">C2C12</Keyword>
        <Keyword MajorTopicYN="N">Differentiation</Keyword>
        <Keyword MajorTopicYN="N">Myoblasts</Keyword>
        <Keyword MajorTopicYN="N">Myotubes</Keyword>
        <Keyword MajorTopicYN="N">REV-ERVα</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32306421</ArticleId>
        <ArticleId IdType="doi">10.1111/boc.201900091</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Anthony, T.G. (2016) Mechanisms of protein balance in skeletal muscle. Domest. Anim. Endocrinol. 56 Suppl, S23-S32.</Citation>
        </Reference>
        <Reference>
          <Citation>Arnone, M.I. and Davidson, E.H. (1997) The hardwiring of development: organization and function of genomic regulatory systems. Development 124, 1851-1864.</Citation>
        </Reference>
        <Reference>
          <Citation>Averous, J., Gabillard, J.-C., Seiliez, I. and Dardevet, D. (2012) Leucine limitation regulates myf5 and myoD expression and inhibits myoblast differentiation. Exp. Cell Res. 318, 217-227.</Citation>
        </Reference>
        <Reference>
          <Citation>Barnea, M., Haviv, L., Gutman, R., Chapnik, N., Madar, Z. and Froy, O. (2012) Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. Biochim. Biophys. Acta 1822, 1796-1806.</Citation>
        </Reference>
        <Reference>
          <Citation>Chatterjee, S., Yin, H., Li, W., Lee, J., Yechoor, V.K. and Ma, K. (2019) The nuclear receptor and clock repressor Rev-erbalpha suppresses myogenesis. Sci. Rep. 9, 4585.</Citation>
        </Reference>
        <Reference>
          <Citation>Cota, D., Proulx, K., Smith, K.A.B., Kozma, S.C., Thomas, G., Woods, S.C., and Seeley, R.J. (2006) Hypothalamic mTOR signaling regulates food intake. Science 312, 927-930.</Citation>
        </Reference>
        <Reference>
          <Citation>Downes, M., Carozzi, A.J. and Muscat, G. (1995) Constitutive expression of the orphan receptor, Rev-erbA alpha, inhibits muscle differentiation and abrogates the expression of the myoD gene family. Mol. Endocrinol. 9, 1666-1678.</Citation>
        </Reference>
        <Reference>
          <Citation>Everett, L.J. and Lazar, M.A. (2014) Nuclear receptor Rev-erbα: up, down, and all around. Trends Endocrinol. Metab. 25, 586-592.</Citation>
        </Reference>
        <Reference>
          <Citation>Ge, Y., Yoon, M.S., and Chen, J. (2011) Raptor and Rheb negatively regulate skeletal myogenesis through suppression of insulin receptor substrate 1 (IRS1) J. Biol. Chem. 286, 35675-35682.</Citation>
        </Reference>
        <Reference>
          <Citation>Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.</Citation>
        </Reference>
        <Reference>
          <Citation>Ivana, L., Carlson, K.A. and Imbalzano, A.N. (2001) Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation. Nat. Genet. 27, 187.</Citation>
        </Reference>
        <Reference>
          <Citation>Jung, C.H., Ro, S.-H., Cao, J., Otto, N.M., and Kim, D.-H. (2010) mTOR regulation of autophagy. FEBS Lett. 584, 1287-1295.</Citation>
        </Reference>
        <Reference>
          <Citation>Kislinger, T., Gramolini, A.O., Pan, Y., Rahman, K., MacLennan, D.H. and Emili, A. (2005) Proteome dynamics during C2C12 myoblast differentiation. Mol. Cell. Proteomics 4, 887-901.</Citation>
        </Reference>
        <Reference>
          <Citation>Laplante, M. and Sabatini, D.M. (2009) mTOR signaling at a glance. J. Cell Sci. 122, 3589-3594.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin, K.A., Rzucidlo, E.M., Merenick, B.L., Fingar, D.C., Brown, D.J., Wagner, R.J. and Powell, R.J. (2004) The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am. J. Physiol. Cell Physiol. 286, C507-517.</Citation>
        </Reference>
        <Reference>
          <Citation>Mayeuf-Louchart, A., Thorel, Q., Delhaye, S., Beauchamp, J., Duhem, C., Danckaert, A., Lancel, S., Pourcet, B., Woldt, E. and Boulinguiez, A. (2017) Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass. Sci. Rep. 7, 14383.</Citation>
        </Reference>
        <Reference>
          <Citation>Mendoza, M.C., Er, E.E.,and Blenis, J. (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320-328.</Citation>
        </Reference>
        <Reference>
          <Citation>Park, I.-H., and Chen, J. (2005) MTOR signaling is required for a late-stage fusion process during skeletal myotube maturation. J. Biol. Chem. 280, 32009-32017.</Citation>
        </Reference>
        <Reference>
          <Citation>Pruitt, K.D., Brown, G.R., Hiatt, S.M., Thibaud-Nissen, F., Astashyn, A., Ermolaeva, O., Farrell, C.M., Hart, J., Landrum, M.J. and McGarvey, K.M. (2014) RefSeq: an update on mammalian reference sequences. Nucleic Acids Res. 42, D756-D763.</Citation>
        </Reference>
        <Reference>
          <Citation>Rion, N., Castets, P., Lin, S., Enderle, L., Reinhard, J.R., Eickhorst, C. and Ruegg, M.A. (2019) mTOR controls embryonic and adult myogenesis via mTORC1. Development 146.</Citation>
        </Reference>
        <Reference>
          <Citation>Rose, A.B. (2019) Introns as gene regulators: a brick on the accelerator. Front. Genet. 9, 672.</Citation>
        </Reference>
        <Reference>
          <Citation>Sabourin, L.A. and Rudnicki, M.A. (2000) The molecular regulation of myogenesis. Clin. Genet. 57, 16-25.</Citation>
        </Reference>
        <Reference>
          <Citation>Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L. and Sabatini, D.M. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501.</Citation>
        </Reference>
        <Reference>
          <Citation>Sherman, H. and Froy, O. (2008) Expression of human beta-defensin 1 is regulated via c-Myc and the biological clock. Mol. Immunol. 45, 3163-3167.</Citation>
        </Reference>
        <Reference>
          <Citation>Shu, L., Zhang, X. and Houghton, P.J. (2002) Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J. Biol. Chem. 277, 16726-16732.</Citation>
        </Reference>
        <Reference>
          <Citation>Wallace, M.A., Hughes, D.C. and Baar, K. (2016) mTORC1 in the control of myogenesis and adult skeletal muscle mass. Molecules to Medicine with mTOR (Elsevier), pp. 37-56.</Citation>
        </Reference>
        <Reference>
          <Citation>Welch, R.D., Billon, C., Valfort, A.-C., Burris, T.P. and Flaveny, C.A. (2017a) Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle. Sci. Rep. 7, 17142.</Citation>
        </Reference>
        <Reference>
          <Citation>Welch, R.D. and Flaveny, C.A. (2017) REV-ERB and ROR: therapeutic targets for treating myopathies. Phys. Biol. 14, 045002.</Citation>
        </Reference>
        <Reference>
          <Citation>Welch, R.D., Guo, C., Sengupta, M., Carpenter, K.J., Stephens, N.A., Arnett, S.A., Meyers, M.J., Sparks, L.M., Smith, S.R. and Zhang, J. (2017b) Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome. Mol. Metab. 6, 703-714.</Citation>
        </Reference>
        <Reference>
          <Citation>Willett, M., Cowan, J.L., Vlasak, M., Coldwell, M.J. and Morley, S.J. (2009) Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Cell. Signal. 21, 1504-1512.</Citation>
        </Reference>
        <Reference>
          <Citation>Woldt, E., Sebti, Y., Solt, L.A., Duhem, C., Lancel, S., Eeckhoute, J., Hesselink, M.K., Paquet, C., Delhaye, S. and Shin, Y. (2013a) Rev-erb-[alpha] modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 19, 1039-1046.</Citation>
        </Reference>
        <Reference>
          <Citation>Woldt, E., Sebti, Y., Solt, L.A., Duhem, C., Lancel, S., Eeckhoute, J., Hesselink, M.K., Paquet, C., Delhaye, S. and Shin, Y. (2013b) Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 19, 1039.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang, H., Li, F., Kong, X., Yuan, X., Wang, W., Huang, R., Li, T., Geng, M., Wu, G., and Yin, Y. (2012) Chemerin regulates proliferation and differentiation of myoblast cells via ERK1/2 and mTOR signaling pathways. Cytokine 60, 646-652.</Citation>
        </Reference>
        <Reference>
          <Citation>Yoon, M.S. (2017) mTOR as a key regulator in maintaining skeletal muscle mass. Front. Physiol. 8, 788.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao, Q., Khorasanizadeh, S., Miyoshi, Y., Lazar, M.A., and Rastinejad, F. (1998) Structural elements of an orphan nuclear receptor-DNA complex. Mol. Cell 1, 849-861.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
